News
Public · Published
Guggenheim maintains Spyre Therapeutics at Buy, raises price target to $135 from $130
Guggenheim kept its Buy rating on Spyre Therapeutics and raised its price target to $135 from $130. The new target is 3.8% higher than the prior target and implies 36.0% upside from the November 3 closing price of $99.27.
Published:
Updated:
What happened
Guggenheim kept its Buy rating on Spyre Therapeutics and raised its price target to $135 from $130. The new target is 3.8% higher than the prior target and implies 36.0% upside from the November 3 closing price of $99.27.
Confirmed
Global impact / market context
A higher target signals that Guggenheim sees more potential value in Spyre shares, which could influence how investors weigh the company’s prospects. However, the target is an analyst estimate, not a guaranteed share price, and the article gives no new company operating or financial results.
Analyst inference
The recent analyst targets cited range from $120 to $121, while Guggenheim’s new $135 target is higher. That difference reflects varied analyst views rather than a change in Spyre’s reported business performance, which the article does not discuss.
Confirmed
What to watch
- Watch for later analyst rating or target changes; a target is an estimate, and shifts could alter investor expectations even without new company results. Analyst inference
- Compare future targets with Spyre Therapeutics’ share price and reported business updates to see whether analysts’ expectations are supported by company developments. Analyst inference
- The article reports recent targets ranging from $120 to $121, compared with Guggenheim’s $135 target, showing a difference among the published analyst estimates. Confirmed
Evidence
- Original source link unavailable